Categories: HealthcareNews

Dimagi Presents Collaborative Behavioral Health and MAT Access Strategies at APHA 2024

Public health technology partner will discuss work in Colorado to improve and modernize behavioral health access

CAMBRIDGE, Mass., Oct. 24, 2024 /PRNewswire/ — Dimagi, a technology partner for public and community health, will present outcomes from its ongoing behavioral health (BH) modernization partnership with the state of Colorado at the 2024 American Public Health Association (APHA) conference. Centered on the show’s theme of “Rebuilding Trust in Public Health and Science,” Dimagi will showcase a poster highlighting how it helped Colorado lower admission times for medication assisted treatment (MAT) enrollees from four days to mere minutes:

Amid record high deaths associated with drug overdoses in Colorado, the state’s Behavioral Health Administration (BHA) sought to address this critical issue by creating a portfolio of digital solutions to better support all stakeholders within the state’s behavioral health infrastructure. The BHA partnered with Dimagi to develop a suite of solutions to modernize operations and improve access to MAT and other behavioral healthcare.

At APHA, Dimagi will present a poster case study exploring a cornerstone solution in its technology suite for Colorado: the state’s centralized MAT registry. Attendees can view the poster and learn more about Dimagi’s partnership and BH modernization approach at the poster session.

About Dimagi

Dimagi is a global social enterprise that powers impactful public health work through innovative and scalable digital solutions and services. Founded in 2002 out of MIT and Harvard Medical School’s joint division Health Science Tech, Dimagi is globally recognized as the maker of CommCare, the most widely-deployed digital platform that empowers a range of critical health programs, from public health and behavioral health to infectious disease management and more. CommCare has provided proven, customizable applications to over 3,000 projects worldwide, helping thousands of frontline workers, governments and NGOs deliver care and enable stronger health outcomes in their communities. One of the first Certified B Corporations established in Massachusetts, Dimagi has partnered with 24 states across the U.S. to improve public health initiatives domestically. Learn more at https://dimagi.com/us-health.

View original content to download multimedia:https://www.prnewswire.com/news-releases/dimagi-presents-collaborative-behavioral-health-and-mat-access-strategies-at-apha-2024-302285848.html

SOURCE Dimagi, Inc.

Staff

Recent Posts

Vent Creativity Appoints Paul Abrams as Vice President of Sales to Lead Commercial Growth

NEW YORK--(BUSINESS WIRE)--Vent Creativity, a medical technology company advancing AI-enabled surgical planning, today announced the…

17 hours ago

AEON Clinic Announces Next Generation Medicine Congress 2026 Event: A Global Convergence on Human Longevity in Dubai

AEON Clinic Elevates Dubai to Global Hub for Longevity Science, A Definitive Four-Day Summit Defining…

17 hours ago

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

2 days ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

2 days ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

2 days ago

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…

2 days ago